Drugs / PA032
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07673458 | Jun → Sep 2026 overdue | — | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PA032 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07673458 ↗ |
| Action | Inhibit | “Kv1.3 potassium channel blocker” NCT07673458 ↗ |
| Route | Topical | “for topical application” NCT07673458 ↗ |